Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
News
TYPE
HEADLINE
FILED AT
8-K
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Updates
8-K
Viking Therapeutics Closes Concurrent Common Stock and Convertible Senior Notes Offerings Raising Over $540 Million in Net Proceeds
8-K
Maintenance study shows VK2735 preserved up to 97% of weight loss with every-other-week dosing and 90% with monthly dosing, with placebo-like GI tolerability.
8-K
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
8-K
Viking Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
Viking Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
424B5
REGISTERED OFFERING
424B5
PENDING FIXED PRICE OFFERING | Bank: Morgan Stanley, J.P. Morgan
424B5
PENDING FIXED PRICE OFFERING | Bank: Morgan Stanley
424B5
6,471,000 Shares
424B5
Common Stock
Registrations
TYPE
HEADLINE
FILED AT
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
DEF 14A
Form DEF 14A - Other definitive proxy statements
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
DEFR14A
Form DEFR14A - Revised definitive proxy soliciting materials
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
